<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="correction"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006754</article-id><article-id pub-id-type="pmc">PMC11860595</article-id><article-id pub-id-type="doi">10.3390/vaccines13020186</article-id><article-id pub-id-type="publisher-id">vaccines-13-00186</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction: Patel et al. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA&#x02013;LNP-Based Vaccines. <italic toggle="yes">Vaccines</italic> 2023, <italic toggle="yes">11</italic>, 1224</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-7850-7420</contrib-id><name><surname>Patel</surname><given-names>Nisarg</given-names></name><xref rid="fn1-vaccines-13-00186" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Zach</given-names></name><xref rid="fn2-vaccines-13-00186" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Hofmann</surname><given-names>Carl</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vlasak</surname><given-names>Josef</given-names></name></contrib><contrib contrib-type="author"><name><surname>Loughney</surname><given-names>John W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>DePhillips</surname><given-names>Pete</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mukherjee</surname><given-names>Malini</given-names></name><xref rid="c1-vaccines-13-00186" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-vaccines-13-00186">Analytical Research &#x00026; Development, Merck &#x00026; Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA; <email>npatel886@live.com</email> (N.P.); <email>zpdavis93@gmail.com</email> (Z.D.); <email>carl.hofmann@merck.com</email> (C.H.); <email>josef_vlasak@merck.com</email> (J.V.); <email>john_loughney@merck.com</email> (J.W.L.); <email>pdsld@comcast.net</email> (P.D.)</aff><author-notes><corresp id="c1-vaccines-13-00186"><label>*</label>Correspondence: <email>malini.mukherjee@merck.com</email></corresp><fn id="fn1-vaccines-13-00186"><label>&#x02020;</label><p>Current address: Technical Development, Spark Therapeutics, 3025 Market Street, Philadelphia, PA 19104, USA.</p></fn><fn id="fn2-vaccines-13-00186"><label>&#x02021;</label><p>Current address: Analytical Outsourcing, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>2</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>13</volume><issue>2</issue><elocation-id>186</elocation-id><history><date date-type="received"><day>22</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><related-article related-article-type="corrected-article" ext-link-type="doi" id="ra1-vaccines-13-00186" xlink:href="10.3390/vaccines11071224" vol="11" page="1224"/></article-meta></front><body><p>The authors would like to make the following corrections to this published paper [<xref rid="B1-vaccines-13-00186" ref-type="bibr">1</xref>].</p><p>In the original publication, there was a mistake in Figure 1H,I as these images were accidentally duplicated. There was also a mistake in the cell line name in Figure 1F. The corrected <xref rid="vaccines-13-00186-f001" ref-type="fig">Figure 1</xref> is attached below.</p><p>The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.</p></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><ref-list><title>Reference</title><ref id="B1-vaccines-13-00186"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Davis</surname><given-names>Z.</given-names></name>
<name><surname>Hofmann</surname><given-names>C.</given-names></name>
<name><surname>Vlasak</surname><given-names>J.</given-names></name>
<name><surname>Loughney</surname><given-names>J.W.</given-names></name>
<name><surname>DePhillips</surname><given-names>P.</given-names></name>
<name><surname>Mukherjee</surname><given-names>M.</given-names></name>
</person-group><article-title>Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA&#x02013;LNP-Based Vaccines</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1224</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11071224</pub-id><pub-id pub-id-type="pmid">37515040</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00186-f001"><label>Figure 1</label><caption><p>LNP transfection curves across varying cell lines indicate variable levels of transfection, which improve with the addition of ApoE during transfection. (<bold>A</bold>) RSV-F protein expression efficiency in Vero, HeLA, HEp-2, A549, CaCo-2 and HepG2 cells was measured by counting percentage of cells positive for RSV-F protein. All cells were transfected for 16 &#x000b1; 2 h with titration of LNPs starting with 200 ng dose of mRNA in media with 2% FBS. Data were fit using variable slope-four parameter logistics regression (4-PL) model in GraphPad Prism software (version: 6.0). (<bold>B</bold>&#x02013;<bold>G</bold>) RSV-F protein expression efficiency following transfection with LNPs in media + 2%FBS, and media + 2%FBS supplemented with ApoE at 4 ug/mL. Hill-slope values [Y = Bottom + (Top &#x02212; Bottom)/(1 + 10^((LogEC50-X) &#x000d7; Hill-slope)] from 4-PL regression are given for curves obtained with FBS supplemented with ApoE. (<bold>B</bold>) HeLa cells. (<bold>C</bold>) Vero cells. (<bold>D</bold>) Hep-2 cells. (<bold>E</bold>) CaCo-2 cells. (<bold>F</bold>) A549 cells. (<bold>G</bold>) HepG2 cells. (<bold>H</bold>) Representative immunofluorescence images of HepG2, Vero and A549 cells without ApoE and (<bold>I</bold>) with ApoE shown at 72 (top row) and 200 ng/mL (bottom row) of mRNA dose representing the bottom and top of the dose response curve, respectively.</p></caption><graphic xlink:href="vaccines-13-00186-g001" position="float"/></fig></floats-group></article>